Significance of indeterminate reactivity to human T-Cell lymphotropic virus in western blot analysis of individuals at risk

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 3, 1997, Pages 249-252

  Medrano, F J ^a   Soriano, V ^b   Calderon E J ^a   Rey, C ^a   Gutierrez M ^b   Bravo, R ^b   Leal, M ^a   Gonzalez Lahoz J ^b   Lissen, E ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOBLOTTING; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS DIAGNOSIS;

ANTIBODIES, VIRAL; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 0030935966     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01709592     Document Type: Article

References (15)

1. Calderón E, Soriano V, Medrano FJ, Leal M: Epidemiology of HTLV-I/II infection in Spain. Alpe Adria Microbiology Journal 1995, 2: 86-94.
2. Maloney EM, Biggar RJ, Neel JV, Taylor ME, Hahn BH, Shawn GM, Blattner WA: Endemic human T-cell lymphotropic virus type II infection among isolated Brazilian Amerindians. Journal of Infectious Diseases 1992, 166: 100-107.
3. Lee H, Swanson R Shorty VS, Zack JA, Rosenblatt JD, Chen ISY: High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989, 244: 471-475.
4. Henrard DR, Soriano V, Robertson E, Gutierrez M, Stephens J, Dronda F, Miles F, Pujol E, Buytendorp M, Castro A, Chan E, Vallejo A, Llibre J, Montley C, Prillaman J, and the HTLV-1 and HTLV-2 Spanish Study Group: Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. Journal of Clinical Microbiology 1995, 33: 1735-1738.
5. Centers for Disease Control and Prevention and the USPHS Working Group: Guidelines for counselling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Annals of Internal Medicine 1993, 118: 448-454.
6. Lal RB, Rudolph DL, Coligan JE, Brodine SK, Roberts CR: Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II. Blood 1992, 80: 544-550.
7. Khabbaz RF, Hartel D, Lairmore M, Horsburgh CR, Schoenbaum EE, Roberts B, Hartley TM, Friedland G: Human T-cell lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: and old infection? Journal of Infectious Diseases 1991, 163: 252-256.
8. Roberts B, Foung S, Lipka J, Kaplan J, Handlock K, Reyes G: Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus type I and type II. Journal of Clinical Microbiology 1993, 31: 260-267.
9. Busch M, Laycok M, Kleinman S, Wages J, Calabro M, Kaplan J, Hollingworth CG, Khabbaz RF: Accuracy of supplementary serologic testing for human T-lymphotropic virus type I and type II in U.S. blood donors. Blood 1994, 83: 1143-1148.
10. Calderón EJ, Rey C, Medrano FJ, Sánchez-Román J, Soriano V, Torres Y, Ruiz M, Lissen E, Leal M: Prevalence of infection by human T-cell leukemia virus types I and II in southern Spain. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 686-690.
11. Kwok S, Kellogg DE, Ehrlich G, Poiesz B, Bhagavatis S, Sninsky JJ: Characterization of a sequence of human T-cell leukemia virus type I from a patient with chronic progressive myelopathy. Journal of Infectious Diseases 1988, 158: 1193-1197.
12. Biggard RJ, Goedert JJ, Hoofnagle J: Accelerated loss of antibody to hepatitis B surface antigens among immunodeficient homosexual men infected with HIV. New England Journal of Medicine 1987, 316: 630-631.
13. Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, Yerly S, Perrin L: Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS 1990, 4: 1275-1277.
14. Buckner C, Roberts CR, Foung SKH, Lipka J, Reyes GR, Hadlock K, Chan L, Gongora-Biachi RA, Hjelle B, Lal RB: Immune responsiveness to the immunodominant recombinant envelope epitopes of HTLV-I and HTLV-II in diverse geographic populations. Journal of Infectious Diseases 1992, 166: 1160-1163.
15. Ehrlich GD, Glaser JB, LaVigne K, Quan D, Mildvan D, Sninsky JJ, Kwok S, Papsidero L, Poiesz BJ: Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction. Blood 1989, 74: 1658-1664.